This page contains a Flash digital edition of a book.
analysis and opinion Porting virtual screening applications


Simon Krige of Cresset BioMolecular Discovery discusses how GPUs are


speeding up the screening and lead optimisation process


parallel computing using graphics processing units, or GPUs, is becoming more important and commonplace. GPUs have the potential to deliver higher performance at lower cost than traditional CPUs in a range of sectors, such as medicine, national security, natural resources and emergency services. Te process of drug discovery in particular


W


is long and laborious. A chemical lead must first be found, oſten by computationally screening millions of chemical compounds against a target. Hundreds or even thousands of compounds must be synthesised around this lead to identify one with the correct properties to become a drug. Tis process typically takes about five years and, if a new drug is discovered, the US FDA approval process then requires another five years of clinical trials. Te parallel computing challenge is to speed up the screening and lead-optimisation process, thus finding new drugs faster and increase the chance of saving lives. Tere are many molecular simulation


and modelling applications that scientists can use to make the drug-discovery process more efficient. Recent improvements have taken these applications a step further by allowing scientists to simulate protein-ligand interactions to a high degree of accuracy, or to computationally screen tens of millions of molecules. Te downfall of these applications is that they require extremely high amounts of computational performance – in fact, very few can do anything useful on a single multi-core CPU machine. A supercomputer consisting of many


interconnected multi-core CPU machines is a solution to this problem, as it can provide enough computational performance to


8 SCIENTIFIC COMPUTING WORLD


hether it’s to determine the fate of the universe, model catastrophic weather conditions or find a new drug to save millions of lives,


produce simulation results on a useful time scale. However, traditional supercomputers can be expensive to buy and operate – requiring continual hardware and soſtware maintenance. With 10 to 20 million researchers and scientists that could benefit from the use of supercomputers, there is significant competition for the shared resources that are available – to the point where, in some cases, researchers have to book time on supercomputers a year in advance. Highly parallel computing with GPUs is


being increasingly recognised as an ideal solution to the problem of resource limitation and cost of traditional supercomputers. Teir many-core architecture makes them ideal parallel processors capable of delivering a


ACCELERATING THE


PACE OF DRUG DISCOVERY IS VITAL FOR HUMANITY AND THE PHARMA INDUSTRY


very appealing number of floating point operations per second. Also, their origin in consumer gaming means that GPUs deliver high performance at a very attractive price point. Originally designed for displaying three- dimensional images and outputting them to a display, the shader pipeline of the GPU is now used for general purpose computing, rather than being hardwired solely to do graphical operations. Powerful soſtware development frameworks have emerged to support GPU- based computing. Te emerging standard is OpenCL, which


is designed for portable, parallel programming of heterogeneous systems combining CPUs and GPUs, and has the potential to unlock the performance benefits of many-core hardware


for scientific applications. Te key advantage of OpenCL is that it allows you to utilise all resources available, maximising the compute performance and cost-to-performance ratio of your computational resources. OpenCL is also the only truly portable and vendor-neutral programming model for GPU and multi-core CPU programming. Te process of efficiently porting serial code


to any parallel programming language can be challenging, and OpenCL is no different. It requires a programmer with excellent knowledge of the underlying hardware architectures and optimisation techniques for parallel computing. GPU computing is fairly new and device drivers can also be unstable. However, the support from vendors and developers is shaping these frameworks for use in commercial applications. At Cresset, we have ported our virtual


screening application BlazeV10 to OpenCL. BlazeV10 uses a molecular similarity algorithm to compare the 3D electrostatic fields of molecules, allowing the user to screen millions of possibilities to locate active molecules accurately and efficiently. Te algorithms are computationally intensive, so it has always required a medium-sized computing cluster to be used effectively, and the port to OpenCL has provided a real-world, 10-fold speed-up when run on a latest-generation, off-the-shelf GPU compared to a recent quad-core CPU. Te shiſt to parallel computing has allowed us to use a single workstation containing four consumer GPUs as a replacement for a 40-node quad-core CPU cluster. Accelerating the pace of drug discovery is


vital for humanity and for the pharmaceutical industry, and GPU computing has an important role to play. As GPU devices continue to increase in performance and ubiquity, they will become an essential tool in the future of sustainable scientific research.


Simon Krige is a software developer at Cresset BioMolecular Discovery in Welwyn, UK. He has a MEng in Computer Science from the University of Bristol and has been a high-performance computing enthusiast for more than two years.


www.cresset-group.com @scwmagazine l www.scientific-computing.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52